FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122765865> ?p ?o ?g. }

• W2122765865 endingPage "2018" @default.
• W2122765865 startingPage "2013" @default.
• W2122765865 abstract "It has been proposed that antioxidants and spin-trap agents may be neuroprotective after acute ischemia stroke. Although the antioxidant ebselen is currently in clinical trials, little is known about the effectiveness of ebselen, which has glutathione peroxidase-like and anti-inflammatory properties in embolic stroke models. Therefore, we determined the effects of ebselen when administered alone or with the thrombolytic tissue plasminogen activator (tPA), the only Food and Drug Administration-approved pharmacological agent for the treatment of stroke.Male New Zealand White rabbits were embolized by injection of a suspension of small blood clots into the middle cerebral artery via a catheter. Five minutes after embolization, ebselen (10 to 50 mg/kg) was infused intravenously. Control rabbits received infusions of the vehicle required to solubilize ebselen. In additional rabbits, ebselen (20 mg/kg) was administered 60 minutes after embolization, either alone or in combination with tPA (0.9 or 3.3 mg/kg tPA). Behavioral analysis was conducted 24 hours after embolization, allowing determination of the effective stroke dose (P50) or clot amount (mg) that produces neurological deficits in 50% of the rabbits.A drug is considered neuroprotective if it significantly increases the P50 compared with the vehicle-treated control group. The P50 of controls 24 hours after embolization was 1.35+/-0.30 mg. Rabbits treated 5 minutes after embolization with 10, 20, or 50 mg/kg ebselen had P50 values of 2.12+/-0.56, 2.82+/-0.75 (P<0.05), and 0.49+/-0.54 mg, respectively. A significant neuroprotective effect was observed with the 20-mg/kg dose, but not if there was a 60-minute delay before administration (P50=1.69+/-0.32 mg). When tPA (3.3 mg/kg) was infused 60 minutes after embolization and ebselen (20 mg/kg) was injected at either 5 (P50=2.98+/-0.18 mg) or 60 (P50=3.60+/-0.79 mg) minutes, there was no additional neuroprotective effect compared with tPA alone (P50=3.38+/-0.55 mg). However, if ebselen (20 mg/kg) was administered concomitantly with low-dose tPA (0.9 mg/kg) 60 minutes after embolization, the P50 was 3.52+/-0.73 mg (P<0.05), indicating a synergistic effect of the drug combination because neither alone was effective (P50=1.69+/-0.32 and 1.54+/-0.36 mg, respectively).This study indicates that ebselen may be neuroprotective when administered shortly after an embolic stroke, but the time- and dose-response analyses suggest that it has a narrow therapeutic window. Nevertheless, ebselen may be beneficial if administered concomitantly with a thrombolytic because it significantly enhanced the neuroprotective activity of low-dose tPA." @default.
• W2122765865 created "2016-06-24" @default.
• W2122765865 creator A5028934169 @default.
• W2122765865 creator A5060081589 @default.
• W2122765865 date "2003-08-01" @default.
• W2122765865 modified "2023-10-16" @default.
• W2122765865 title "Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits" @default.
• W2122765865 cites W1848977294 @default.
• W2122765865 cites W1977731043 @default.
• W2122765865 cites W1990484506 @default.
• W2122765865 cites W2001300453 @default.
• W2122765865 cites W2004422759 @default.
• W2122765865 cites W2016853025 @default.
• W2122765865 cites W2020201638 @default.
• W2122765865 cites W2043337210 @default.
• W2122765865 cites W2055609777 @default.
• W2122765865 cites W2061952296 @default.
• W2122765865 cites W2066947595 @default.
• W2122765865 cites W2074463413 @default.
• W2122765865 cites W2080155250 @default.
• W2122765865 cites W2082443643 @default.
• W2122765865 cites W2111584692 @default.
• W2122765865 cites W2112646710 @default.
• W2122765865 cites W2114907498 @default.
• W2122765865 cites W2129598039 @default.
• W2122765865 cites W2134164486 @default.
• W2122765865 cites W2144859488 @default.
• W2122765865 cites W2159515166 @default.
• W2122765865 cites W2408805972 @default.
• W2122765865 cites W4236110459 @default.
• W2122765865 doi "https://doi.org/10.1161/01.str.0000081223.74129.04" @default.
• W2122765865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12855833" @default.
• W2122765865 hasPublicationYear "2003" @default.
• W2122765865 type Work @default.
• W2122765865 sameAs 2122765865 @default.
• W2122765865 citedByCount "81" @default.
• W2122765865 countsByYear W21227658652012 @default.
• W2122765865 countsByYear W21227658652013 @default.
• W2122765865 countsByYear W21227658652014 @default.
• W2122765865 countsByYear W21227658652015 @default.
• W2122765865 countsByYear W21227658652016 @default.
• W2122765865 countsByYear W21227658652017 @default.
• W2122765865 countsByYear W21227658652018 @default.
• W2122765865 countsByYear W21227658652020 @default.
• W2122765865 countsByYear W21227658652021 @default.
• W2122765865 countsByYear W21227658652022 @default.
• W2122765865 countsByYear W21227658652023 @default.
• W2122765865 crossrefType "journal-article" @default.
• W2122765865 hasAuthorship W2122765865A5028934169 @default.
• W2122765865 hasAuthorship W2122765865A5060081589 @default.
• W2122765865 hasBestOaLocation W21227658651 @default.
• W2122765865 hasConcept C126322002 @default.
• W2122765865 hasConcept C127413603 @default.
• W2122765865 hasConcept C141071460 @default.
• W2122765865 hasConcept C185592680 @default.
• W2122765865 hasConcept C25498285 @default.
• W2122765865 hasConcept C2775838275 @default.
• W2122765865 hasConcept C2775841333 @default.
• W2122765865 hasConcept C2776035437 @default.
• W2122765865 hasConcept C2776151105 @default.
• W2122765865 hasConcept C2776572282 @default.
• W2122765865 hasConcept C2778004101 @default.
• W2122765865 hasConcept C2778760513 @default.
• W2122765865 hasConcept C2779138974 @default.
• W2122765865 hasConcept C2780645631 @default.
• W2122765865 hasConcept C42219234 @default.
• W2122765865 hasConcept C541997718 @default.
• W2122765865 hasConcept C55493867 @default.
• W2122765865 hasConcept C71924100 @default.
• W2122765865 hasConcept C78519656 @default.
• W2122765865 hasConcept C98274493 @default.
• W2122765865 hasConceptScore W2122765865C126322002 @default.
• W2122765865 hasConceptScore W2122765865C127413603 @default.
• W2122765865 hasConceptScore W2122765865C141071460 @default.
• W2122765865 hasConceptScore W2122765865C185592680 @default.
• W2122765865 hasConceptScore W2122765865C25498285 @default.
• W2122765865 hasConceptScore W2122765865C2775838275 @default.
• W2122765865 hasConceptScore W2122765865C2775841333 @default.
• W2122765865 hasConceptScore W2122765865C2776035437 @default.
• W2122765865 hasConceptScore W2122765865C2776151105 @default.
• W2122765865 hasConceptScore W2122765865C2776572282 @default.
• W2122765865 hasConceptScore W2122765865C2778004101 @default.
• W2122765865 hasConceptScore W2122765865C2778760513 @default.
• W2122765865 hasConceptScore W2122765865C2779138974 @default.
• W2122765865 hasConceptScore W2122765865C2780645631 @default.
• W2122765865 hasConceptScore W2122765865C42219234 @default.
• W2122765865 hasConceptScore W2122765865C541997718 @default.
• W2122765865 hasConceptScore W2122765865C55493867 @default.
• W2122765865 hasConceptScore W2122765865C71924100 @default.
• W2122765865 hasConceptScore W2122765865C78519656 @default.
• W2122765865 hasConceptScore W2122765865C98274493 @default.
• W2122765865 hasIssue "8" @default.
• W2122765865 hasLocation W21227658651 @default.
• W2122765865 hasLocation W21227658652 @default.
• W2122765865 hasOpenAccess W2122765865 @default.
• W2122765865 hasPrimaryLocation W21227658651 @default.
• W2122765865 hasRelatedWork W1566070479 @default.
• W2122765865 hasRelatedWork W1965348397 @default.

• next